Clinical Trial Update: Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating pegylated liposomal doxorubicin (PLD) plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• PLD (pegylated liposomal doxorubicin)

Snippet

Sponsor: Women's Hospital School Of Medicine Zhejiang University | Conditions: Efficacy and Safety | Phase 4 | Status: UNKNOWN